Use of intravenous iron and risk of anaphylaxis

Autor: Nicholas Moore, Patrick Blin, Jochen Dress, Antje Timmer, Jacques Benichou, Jonas Reinold, Ron M.C. Herings, Edeltraut Garbe, Ingvild Odsbu, Susana Perez-Gutthann, Nuria Saigi-Morgui, Gunnar Toft, Vera Ehrenstein, Cécile Droz-Perroteau, Andreas J. Bircher, D. S. Rampton, Michael Forstner, Carla Franzoni, Elisabeth Smits, Joan Fortuny, Régis Lassalle, Katherine Rascher, Gero von Gersdorff, Mathias Schaller, Kenneth J. Rothman, Jetty A. Overbeek, Tania Schink, Marie Linder, Bianca Kollhorst, Lawrence Rasouliyan, Lia Gutierrez

Publikováno v: Pharmacoepidemiology and Drug Safety
Pharmacoepidemiology and Drug Safety, Wiley, 2021, ⟨10.1002/pds.5319⟩
Pharmacoepidemiology and Drug Safety, 30(10), 1447-1457. John Wiley and Sons Ltd
Intravenous Iron Consortium 2021, ' Use of intravenous iron and risk of anaphylaxis : A multinational observational post-authorisation safety study in Europe ', Pharmacoepidemiology and Drug Safety, vol. 30, no. 10, pp. 1447-1457 . https://doi.org/10.1002/pds.5319

International audience; PURPOSE: This post-authorisation safety study estimated the risk of anaphylaxis in patients receiving intravenous (IV) iron in Europe, with interest in iron dextran and iron non-dextrans. Studies conducted in the United States

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06c312f47a90c0a8bc0e2ccf6427694
https://doi.org/10.1002/pds.5319

Evaluation of new therapies for inflammatory bowel disease

Autor: D. S. Rampton, E. Carty

Publikováno v: British Journal of Clinical Pharmacology. 56:351-361

The pathophysiology of inflammatory bowel disease (IBD) is gradually being unravelled and new therapies are being developed to target the disturbed biological processes. This article outlines the clinical features of IBD, its current therapy and path

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95939ae3170733358ad8cf67bd6e0f8c
https://doi.org/10.1046/j.1365-2125.2003.01965.x

Review article: herbal treatment in gastrointestinal and liver disease-benefits and dangers

Autor: D. S. Rampton, L. Langmead

Publikováno v: Alimentary Pharmacology & Therapeutics. 15:1239-1252

Herbal medicines are now used by up to 50% of the Western population, in a substantial minority of instances for the treatment or prevention of digestive disorders. Although most indications for the use of such remedies are anecdotally or traditional

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a77432cc7708c06e4c4e1ceee493b10
https://doi.org/10.1046/j.1365-2036.2001.01053.x

Effects of iron and iron chelation in vitro on mucosal oxidant activity in ulcerative colitis

Autor: D R Blake, D. S. Rampton, A D Millar

Publikováno v: Alimentary Pharmacology & Therapeutics. 14:1163-1168

Background: Reactive oxygen species may be pathogenic in ulcerative colitis. Oral iron supplements anecdotally exacerbate inflammatory bowel disease and iron levels are elevated in the inflamed mucosa. Mucosal iron may enhance hydroxyl ion production

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc57f09296454868f6058f0d400bf918
https://doi.org/10.1046/j.1365-2036.2000.00828.x

Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies

Autor: A D Millar, D. S. Rampton, N. J. Simmonds, D R Blake

Publikováno v: Alimentary Pharmacology & Therapeutics. 13:363-372

Background : The therapeutic efficacy of 5-aminosalicylic acid in inflammatory bowel disease may be related to its antioxidant properties. Aim : To compare in vitro the antioxidant effects of conventional drugs (5-aminosalicylic acid, corticosteroids

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bae4c20324fde6224bba7145344f589f
https://doi.org/10.1046/j.1365-2036.1999.00484.x